NeoGenomics (NASDAQ:NEO) Stock Gets Downgrade from Wall Street Zen

NeoGenomics (NASDAQ:NEO) was downgraded by investment analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued on Saturday, Wall Street Zen reports.

A number of other equities research analysts have also recently issued reports on NEO. Weiss Ratings reissued a “sell (d-)” rating on shares of NeoGenomics in a research report on Monday, October 12th. Zacks Research lowered NeoGenomics from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 28th. TD Cowen boosted their price objective on shares of NeoGenomics from $19.00 to $23.00 and gave the company a “buy” rating in a research report on Thursday. Benchmark raised their price objective on NeoGenomics from $11.00 to $16.00 and gave the stock a “buy” rating in a report on Friday, July 24th. Finally, BTIG Research reiterated a “buy” rating and set a $28.00 price target on shares of NeoGenomics in a research report on Thursday. Eight equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $20.88.

NeoGenomics Stock Performance

Shares of NEO stock opened at $17.38 on Friday. NeoGenomics has a 52-week low of $7.07 and a 52-week high of $20.15. The company has a quick ratio of 3.31, a current ratio of 3.53 and a debt-to-equity ratio of 0.47. The stock’s 50-day moving average price is $17.68 and its 200 day moving average price is $12.82. The stock has a market capitalization of $2.25 billion, a PE ratio of -69.52 and a beta of 1.87.

NeoGenomics (NASDAQ:NEO) last announced its quarterly earnings data on Wednesday, October 28th. The medical research company reported $0.07 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.01. The company had revenue of $209.25 million during the quarter, compared to analyst estimates of $206.70 million. NeoGenomics had a negative net margin of 4.10% and a negative return on equity of 0.99%. The firm’s revenue for the quarter was up 11.3% compared to the same quarter last year. During the same period last year, the business earned $0.03 EPS. As a group, equities research analysts forecast that NeoGenomics will post -0.09 EPS for the current year.

Institutional Trading of NeoGenomics

Several hedge funds and other institutional investors have recently made changes to their positions in NEO. Root Financial Partners LLC purchased a new stake in NeoGenomics in the third quarter worth about $29,000. Farther Finance Advisors LLC grew its holdings in shares of NeoGenomics by 117.0% during the third quarter. Farther Finance Advisors LLC now owns 1,701 shares of the medical research company’s stock worth $31,000 after buying an additional 917 shares in the last quarter. GAMMA Investing LLC boosted its position in NeoGenomics by 30.1% in the 3rd quarter. GAMMA Investing LLC now owns 2,782 shares of the medical research company’s stock valued at $51,000 after buying an additional 644 shares during the last quarter. Allworth Financial LP boosted its holdings in shares of NeoGenomics by 110.4% during the second quarter. Allworth Financial LP now owns 4,132 shares of the medical research company’s stock valued at $60,000 after acquiring an additional 2,168 shares during the period. Finally, MQS Management LLC acquired a new position in NeoGenomics in the 1st quarter worth approximately $75,000. Hedge funds and other institutional investors own 98.50% of the company’s stock.

Trending Headlines about NeoGenomics

Here are the key news stories impacting NeoGenomics this week:

• Positive Sentiment: Q3 results exceeded expectations. NeoGenomics reported third-quarter revenue of approximately $209 million, up 11.3% year over year, while earnings per share of $0.07 topped the $0.06 consensus estimate. NeoGenomics third-quarter earnings results
• Positive Sentiment: Management raised its full-year outlook. The company increased 2026 revenue guidance to $807 million-$809 million, signaling continued demand for its cancer-testing and laboratory-services business. The improved outlook was highlighted alongside the earnings beat. NeoGenomics raises 2026 guidance
• Positive Sentiment: Analyst support remains strong. BTIG Research reaffirmed its “Buy” rating and maintained a $28 price target, implying substantial upside from recent trading levels. Investors also continue to assess whether the earnings beat and higher guidance leave the stock attractively valued. BTIG Research rating
• Neutral Sentiment: CEO transition planned for January 2027. NeoGenomics disclosed that its chief executive transition is expected early next year. The change could eventually support new strategic initiatives, but investors may initially seek more clarity on succession and execution. NeoGenomics 2026 third-quarter earnings presentation
• Negative Sentiment: Profitability remains a concern. Although adjusted quarterly earnings beat estimates, the company continues to face pressure from weak reported profitability, with a negative net margin and analysts expecting a full-year loss. This may be limiting the stock’s reaction to the stronger revenue outlook.

About NeoGenomics

NeoGenomics, Inc (NASDAQ: NEO) is a cancer-focused diagnostics company that provides laboratory testing and related services to oncologists, hospitals, academic institutions, and biopharmaceutical companies. Its diagnostic offerings support the detection, classification, and monitoring of cancer and help inform treatment decisions.

The company’s services include pathology, immunohistochemistry, flow cytometry, cytogenetics, molecular testing, and other specialized oncology assays. NeoGenomics also provides clinical trial and pharmaceutical services, including biomarker testing, central laboratory support, and companion diagnostic development for drug developers.

Founded in 1999, NeoGenomics has expanded through internal growth and acquisitions and operates a network of clinical laboratories serving customers primarily in the United States, with additional international capabilities.